Testosterone replacement therapy in patients with prostate cancer after radical prostatectomy

Journal of Urology

Volumn 190, Issue 2, 2013, Pages 639-644

  Pastuszak, Alexander W ^a   Pearlman, Amy M ^c   Lai, Win Shun ^a   Godoy, Guilherme ^a   Sathyamoorthy, Kumaran ^a   Liu, Joceline S ^d   Miles, Brian J ^b   Lipshultz, Larry I ^a   Khera, Mohit ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b HOUSTON METHODIST HOSPITAL   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d NORTHWESTERN UNIVERSITY   (United States)

Author keywords

hormone replacement therapy; hypogonadism; prostatectomy; prostatic neoplasms; testosterone

Indexed keywords

HEMOGLOBIN; PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE;

ADULT; ANDROGEN THERAPY; ARTICLE; CANCER RECURRENCE; CANCER RISK; CLINICAL ARTICLE; CLINICAL PROTOCOL; HEMATOCRIT; HIGH RISK PATIENT; HORMONE BLOOD LEVEL; HUMAN; HYPOGONADISM; LABORATORY TEST; LOW RISK POPULATION; MALE; MEDICAL RECORD REVIEW; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; RETROSPECTIVE STUDY;

ADT; ANDROGEN DEPRIVATION THERAPY; BCR; BIOCHEMICAL RECURRENCE; CAP; HCT; HEMATOCRIT; HEMOGLOBIN; HGB; HORMONE REPLACEMENT THERAPY; HYPOGONADISM; PROSTATE CANCER; PROSTATE SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; PSA; PSA VELOCITY; PSAV; RADICAL PROSTATECTOMY; RP; T; TESTOSTERONE; TESTOSTERONE REPLACEMENT THERAPY; TRT;

AGED; HEMATOCRIT; HEMOGLOBINS; HORMONE REPLACEMENT THERAPY; HUMANS; HYPOGONADISM; LINEAR MODELS; MALE; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; STATISTICS, NONPARAMETRIC; TESTOSTERONE; TREATMENT OUTCOME;

EID: 84880036090     PISSN: 00225347     EISSN: 15273792     Source Type: Journal    
DOI: 10.1016/j.juro.2013.02.002     Document Type: Article

References (27)

1. C. Wang, E. Nieschlag, R. Swerdloff Investigation, treatment, and monitoring of late-onset hypogonadism in males: ISA, ISSAM, EAU, EAA, and ASA recommendations J Androl 30 2009 1
2. C. Huggins, C.V. Hodges Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941 J Urol 168 2002 9
3. J.E. Fowler Jr, W.F. Whitmore Jr The response of metastatic adenocarcinoma of the prostate to exogenous testosterone J Urol 126 1981 372
4. G.R. Prout Jr, W.R. Brewer Response of men with advanced prostatic carcinoma to exogenous administration of testosterone Cancer 20 1967 1871
5. S. Bhasin, G.R. Cunningham, F.J. Hayes Testosterone therapy in adult men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline J Clin Endocrinol Metab 91 2006 1995
6. E.L. Rhoden, A. Morgentaler Risks of testosterone-replacement therapy and recommendations for monitoring N Engl J Med 350 2004 482
7. E.L. Rhoden, A. Morgentaler Testosterone replacement therapy in hypogonadal men at high risk for prostate cancer: results of 1 year of treatment in men with prostatic intraepithelial neoplasia J Urol 170 2003 2348
8. O.M. Calof, A.B. Singh, M.L. Lee Adverse events associated with testosterone replacement in middle-aged and older men: a meta-analysis of randomized, placebo-controlled trials J Gerontol A Biol Sci Med Sci 60 2005 1451
9. M.J. Curran, W. Bihrle 3rd Dramatic rise in prostate-specific antigen after androgen replacement in a hypogonadal man with occult adenocarcinoma of the prostate Urology 53 1999 423
10. N. Bassil, S. Alkaade, J.E. Morley The benefits and risks of testosterone replacement therapy: a review Ther Clin Risk Manag 5 2009 427
11. W.J. Hellstrom, D. Paduch, C.F. Donatucci Importance of hypogonadism and testosterone replacement therapy in current urologic practice: a review Int Urol Nephrol 44 2012 61
12. M. Khera, E.D. Grober, B. Najari Testosterone replacement therapy following radical prostatectomy J Sex Med 6 2009 1165
13. P.K. Agarwal, M.G. Oefelein Testosterone replacement therapy after primary treatment for prostate cancer J Urol 173 2005 533
14. J.M. Kaufman, R.J. Graydon Androgen replacement after curative radical prostatectomy for prostate cancer in hypogonadal men J Urol 172 2004 920
15. M.F. Sarosdy Testosterone replacement for hypogonadism after treatment of early prostate cancer with brachytherapy Cancer 109 2007 536
16. A. Morales, A.M. Black, L.E. Emerson Testosterone administration to men with testosterone deficiency syndrome after external beam radiotherapy for localized prostate cancer: preliminary observations BJU Int 103 2009 62
17. A. Patel, F. Dorey, J. Franklin Recurrence patterns after radical retropubic prostatectomy: clinical usefulness of prostate specific antigen doubling times and log slope prostate specific antigen J Urol 158 1997 1441
18. M.S. Cookson, G. Aus, A.L. Burnett Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: the American Urological Association Prostate Guidelines for Localized Prostate Cancer Update Panel report and recommendations for a standard in the reporting of surgical outcomes J Urol 177 2007 540
19. G.D. Grossfeld, D.M. Latini, D.P. Lubeck Predicting recurrence after radical prostatectomy for patients with high risk prostate cancer J Urol 169 2003 157
20. O. Dillioglugil, B.D. Leibman, M.W. Kattan Hazard rates for progression after radical prostatectomy for clinically localized prostate cancer Urology 50 1997 93
21. L. Budäus, H. Isbarn, P. Tennstedt Risk assessment of metastatic recurrence in patients with prostate cancer by using the Cancer of the Prostate Risk Assessment score: results from 2937 European patients BJU Int 110 2012 1714
22. S. Vesely, L. Jarolim, M. Schmidt Parameters derived from the postoperative decline in ultrasensitive PSA improve the prediction of radical prostatectomy outcome World J Urol 31 2013 299
23. J. Gore, J. Rajfer Rising PSA during testosterone replacement therapy Rev Urol 6 suppl. 2004 S41
24. M. Banerjee, I.J. Powell, J. George Prostate specific antigen progression after radical prostatectomy in African-American men versus white men Cancer 94 2002 2577
25. L.S. Marks, N.A. Mazer, E. Mostaghel Effect of testosterone replacement therapy on prostate tissue in men with late-onset hypogonadism: a randomized controlled trial JAMA 296 2006 2351
26. A. Morgentaler, A.M. Traish Shifting the paradigm of testosterone and prostate cancer: the saturation model and the limits of androgen-dependent growth Eur Urol 55 2009 310
27. A. Morgentaler, A. Morales Should hypogonadal men with prostate cancer receive testosterone? J Urol 184 2010 1257